Complete the form to request a meeting to discuss how DELFI's platform can enhance your lung cancer screening programs or research initiatives.
© 2026 DELFI Diagnostics, Inc. All rights reserved. FirstLook is a trademark of DELFI Diagnostics, Inc. used worldwide.
Not affiliated with or endorsed by AACR.
General Inquiry: clientservices@delfidiagnostics.com
1810 Embarcadero Road, Suite 100
Palo Alto, CA 94303
800-589-2182
Follow us:
DELFI Diagnostics is a pioneering leader in cancer detection and monitoring through fragmentomics. Our technology analyzes unique DNA fragmentation patterns in the bloodstream to help detect cancer earlier and monitor treatment effectiveness with high sensitivity. DELFI's non-invasive liquid biopsy approach aims to improve patient outcomes and accelerate pharmaceutical development through data-driven insights powered by machine learning and genome-wide analysis.
DELFI-TF is a tumor-naive and mutation-independent cancer treatment monitoring assay that can detect disease progression ahead of imaging assessment (RECIST). DELFI Diagnostics is collaborating with several pharmaceutical companies to apply the DELFI-TF as a pharmacodynamic monitoring tool for the portfolio management of Phase I-II clinical trials.
Commercialized in 2023, the FirstLook Lung blood test is designed to be a convenient first step that can be offered to patients during a routine medical visit to help identify lung cancer early, when it’s most treatable.
Learn More About DELFI’s AI-Powered, Fragmentomics Platform
Poster Presentations at AACR 2026
Sunday, April 27: 12:00 PM - 5:00 PM
Monday, April 28: 9:00 AM - 5:00 PM
Tuesday, April 29: 9:00 AM - 5:00 PM
Wednesday, April 30: 9:00 AM - 12:00 PM
Visit Our Booth & Meet DELFI’s Researchers
Booth Information
DELFI Expert Office Hour
Two DELFI founders and researchers will host office hours at our booth to answer your questions about DELFI's science, products and services.
Tuesday, April 29
12:00 - 1:00 PM CT
| Presenter | Title | Session Title | Date & Time | Poster Section | Board # | Poster # |
|---|---|---|---|---|---|---|
| Valsamo Anagnostou (JHU) | Cell-free DNA fragmentome profiles predict immunotherapy response | Liquid Biopsies: Circulating Nucleic Acids 1 | 4/19/2026 2–5 PM |
44 | 15 | 1134 |
| Laurel Millberg (DELFI) | Lung Cancer Subtyping using cell-free DNA fragmentomes and Protein Biomarkers | Liquid Biopsies: Circulating Nucleic Acids 1 | 4/19/2026 2–5 PM |
44 | 16 | 1135 |
| Jaime Wehr (JHU) | Clinical utility of landmark ctDNA molecular response as an early indicator of immunotherapy outcomes in lung cancer | Liquid Biopsy: Multi-Analyte and Multi-Omic | 4/19/2026 2–5 PM |
5 | 17 | 110 |
| Laurel Millberg (DELFI) | Enhanced cfDNA Fragmentation-based Treatment Monitoring on the Ultima Genomics Platform | Liquid Biopsies: Circulating Nucleic Acids 3 | 4/20/2026 2–5 PM |
45 | 24 | 3863 |
| Denise van Steijn (NKI) | Cell-free DNA fragmentomes for treatment response monitoring in patients with metastatic colorectal cancer: the multicenter, prospective, observational DOLPHIN study | Liquid Biopsies: Circulating Nucleic Acids 4 | 4/21/2026 9 AM–12 PM |
45 | 20 | 5325 |
